Proactively manage your pharmacy inventory
Manage your formulary budget
Find generic entry opportunities
Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Method of treating chronic fatigue syndrome|
|Abstract:||The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject comprising administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and a greater inhibition of norepinephrine reuptake than serotonin reuptake, and wherein said compound is not administered adjunctively with phenylalanine or tyrosine. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.|
|Inventor(s):||Kranzler; Jay D. (La Jolla, CA), Rao; Srinivas G. (San Diego, CA)|
|Assignee:||Cypress Bioscience, Inc. (San Diego, CA)|
|Filing Date:||Nov 05, 2001|
|Claims:||1. A method of treating chronic fatigue syndrome (CFS) comprising administering to an animal subject suffering from CFS, a composition wherein the active ingredient consists of milnacipran, or a pharmaceutically acceptable salt thereof in an amount effective to treat pain or fatigue associated with CFS. |
2. The method according to claim 1, wherein the animal subject is a human.
3. The method according to claim 1, wherein the amount of milnacipran administered is from about 25 mg to about 400 mg per day.
4. The method according to claim 1, wherein the compound is formulated in a release dosage formulation.
5. The method according to claim 1, wherein the amount of milnacipran administered is from about 100 mg to about 250 mg per day.